Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ompenaclid vs placebo + FOLFIRI + bevacizumab in RAS-mutant metastatic colorectal cancer
2023-503356-27-00Phase 2Completed
- Sponsor
- Inspirna
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing Ompenaclid + FOLFIRI + bevacizumab with Placebo + FOLFIRI + bevacizumab (2 arms). Primary endpoint: Overall response rate. Started Jul 2023; status: completed.
02
Drugs
ompenaclid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-503356-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503356-27-00.